IPO
Guardant Health went on the Nasdaq yesterday under the symbol GH. Shares climbed almost 70 percent on the first day of trading, selling 12.5 million shares at $19 per share in the initial public offering (IPO).
Feedback plc (AIM: FDBK, “Feedback” or the “Company”), the specialist medical imaging technology company, announces a trading update for the year ended 31 May 2018 and the period to 30 September 2018.
Six months after officially launching and one month after securing $120 million in private financing, Allogene Therapeutics is looking to score between $272 and $288 million from an initial public offering.
Immunicum AB today announced that Nasdaq Stockholm decided to halt trading in the Company’s share as a result of share price movements.
A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.
Gamida Cell Ltd. filed for a $69 million initial public offering for the Nasdaq exchange, according to a filing submitted last week to the U.S. Securities and Exchange Commission, Israel’s Calcalist first reported last week.
Gritstone Oncology, Inc. today announced the pricing of its initial public offering of 6,666,667 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions.
Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.
Fusion Antibodies plc announces that it has been informed by Alan Mawson, a Non-Executive Director of the Company, that on 24 September 2018 he purchased 8,500 ordinary shares in the Company (“Ordinary Shares”) at a price of 67 pence per Ordinary Share via his personal pension scheme.
Karolinska Development’s portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm.
PRESS RELEASES